NCT02168738 (AceDoPC) is a NA clinical trial of 13-C labeled AceDoPC-DHA in Healthy Subject, sponsored by Hospices Civils de Lyon.

Who is sponsoring NCT02168738?

NCT02168738 is sponsored by Hospices Civils de Lyon.

What drugs are being tested in NCT02168738?

Interventions in NCT02168738: 13-C labeled AceDoPC-DHA, 13-C labeled TG-DHA, 13-C labeled PC-DHA.

What condition does NCT02168738 study?

NCT02168738 studies Healthy Subject.

Is NCT02168738 still recruiting?

NCT02168738 is currently completed. Last updated 13 December 2025.

Last reviewed 2025-12-13 · How we verify

NCT02168738: AceDoPC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bioavailability of DHA-TG (Docosahexaenoic Triglyceride), DHA-PC (Docosahexaenoic Phosphatidylcholine) and AcedoPC (1-acetyl-2-docosahexaenoic-glycerophosphocholine) in Human

Completed NA Last updated 13 December 2025

What this trial tests

NA trial testing 13-C labeled AceDoPC-DHA in Healthy Subject in 4 participants. Completed in 1 April 2015.

Timeline

1 March 2014

Primary endpoint
1 April 2015

1 April 2015

Quick facts

Lead sponsor	Hospices Civils de Lyon
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Primary purpose	basic science
Enrollment	4
Start date	1 March 2014
Primary completion	1 April 2015
Estimated completion	1 April 2015
Sites	1 location across France

Drugs / interventions tested

13-C labeled AceDoPC-DHA — full drug profile →
13-C labeled TG-DHA — full drug profile →
13-C labeled PC-DHA — full drug profile →

Conditions studied

Healthy Subject — all drugs for Healthy Subject →

Sponsor

Hospices Civils de Lyon — full company profile →

Who can join

Adults 60 to 70, male only, with Healthy Subject. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Concentration of 13C-DHA in red blood cells
Time frame: At Day 1
6 hours after product ingestion

Sponsor's own description

The purpose of this study is to compare three lipidic forms of DHA in their metabolic pathway in human by using 13C labeled molecules. The circulating form of DHA plays a major role in his cerebral incorporation. The aim of this research is to confirm that some lipidic forms are best carriers for the cerebral incorporation in studying 13C-DHA distribution in plasma lipids and blood cells.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Docosahexaenoic Acid (DHA) Bioavailability in Humans after Oral Intake of DHA-Containing Triacylglycerol or the Structured Phospholipid AceDoPC<sup>®</sup>.
Hachem M, Nacir H, Picq M, Belkouch M, et al · · 2020 · cited 19× · PMID 31963708 · DOI 10.3390/nu12010251

Verify or expand the search:

Other recruiting trials for Healthy Subject

Currently open trials in the same condition.

NCT03897270 — Photoacoustic Imaging of the Breast in Patients With Breast Cancer and Healthy Subjects · NA · recruiting
NCT03303846 — Combined Breast MRI and Biomarker Strategies in Identifying High-risk Breast Cancer Patients · NA · active not recruiting
NCT03491176 — Magnetic Resonance (MR) Imaging & Blood Biomarkers for Head and Neck Cancer · active not recruiting
NCT03207854 — Collection of Immunology Specimens From Patients With Cancer or Blood Disorders, and Healthy Volunteers · recruiting
NCT03199365 — Tu Salud Si Cuenta Intervention in Increasing Physical Activity and Healthy Eating Among Latino Families · NA · active not recruiting

Other Hospices Civils de Lyon trials

Trials by the same sponsor.

NCT07569536 — Efficacy of the Alpha 2 Agonist Dexmedetomidine for Sympathetic Deactivation in REfractory Septic Shock · Phase 3 · not yet recruiting
NCT07529314 — Evaluating Interventional Radiology for Cancer Pain Management · NA · not yet recruiting
NCT07273929 — Comparative Study of the Effectiveness of Three Access Routes for Implanting an Electronic Intracardiac Device · Phase 3 · not yet recruiting
NCT07474532 — Attitudes and Beliefs Related to Benzodiazepine Deprescribing · not yet recruiting
NCT07313007 — Assessment of Gut Microbiota-Derived Amino Acid Metabolite Production in Patients With MASLD · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02168738 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hospices Civils de Lyon
Last refreshed: 13 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02168738.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing